Cargando…

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer

The B-type Raf kinase (BRAF) V600E mutation is a well-established biomarker for poor prognosis in metastatic colorectal cancer (mCRC) and is a highly attractive drug target. A barrier to the development of new therapies targeting BRAF V600E in mCRC is the low prevalence of mutations (approximately 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Day, Fiona, Muranyi, Andrea, Singh, Shalini, Shanmugam, Kandavel, Williams, David, Byrne, David, Pham, Kym, Palmieri, Michelle, Tie, Jeanne, Grogan, Thomas, Gibbs, Peter, Sieber, Oliver, Waring, Paul, Desai, Jayesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363480/ https://www.ncbi.nlm.nih.gov/pubmed/24859797 http://dx.doi.org/10.1007/s11523-014-0319-8

Ejemplares similares

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
por: Tan, Lavinia, et al.
Publicado: (2023)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Immunohistochemical Investigation of Mutant BRAF V600E in Common Pigmented Skin Neoplasms, Study on a Sample of Iranian Patients
por: Ghasemi, Maryam, et al.
Publicado: (2019)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
por: Bui Dang Minh, Tri, et al.
Publicado: (2023)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

Adult Onset of BRAF(V600E)-Mutated Langerhans Cell Histiocytosis with Cutaneous Involvement Successfully Diagnosed by Immunohistochemical Staining
por: Tono, Hisayuki, et al.
Publicado: (2015)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
por: Ahn, Jun-Ho, et al.
Publicado: (2015)

Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study
por: Shirsat, Pankaj M, et al.
Publicado: (2018)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

An approach to suppress the evolution of resistance in BRAF(V600E)-mutant cancer
por: Xue, Yaohua, et al.
Publicado: (2017)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
por: Simpson, Dennis A., et al.
Publicado: (2015)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
por: DiPeri, Timothy P., et al.
Publicado: (2022)

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
por: Robinson, Giles W, et al.
Publicado: (2014)

Dual inhibition of BRAF and mTOR in BRAF(V600E)-mutant pediatric, adolescent, and young adult brain tumors
por: Sen, Shiraj, et al.
Publicado: (2020)

Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
por: Yang, Meijia, et al.
Publicado: (2017)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study
por: Obadofin, O., et al.
Publicado: (2019)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bi3rhnoqkqfie6mkl7d2s0sm1d